Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

NCT02030847 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options

Interventions

BIOLOGICAL: CART-19
BIOLOGICAL: CART-19
BIOLOGICAL: CART-19
BIOLOGICAL: CART-19

Sponsor

University of Pennsylvania